Journal Mobile Options
Table of Contents
Vol. 36, No. 5, 1999
Issue release date: November 1999 (September 1999)

Factors Influencing the Course of Calcium Oxalate Stone Disease

Tiselius H.-G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To assess the influence of previous stone formation, urine and stone composition on the further course of the disease in recurrent calcium stone formers without pharmacological treatment. Method: The course of the disease was analysed during a prospective follow-up period by means of Kaplan-Meier estimates. At the start of follow-up the patients were subgrouped with regard to their previous history of stone formation expressed as stone age index (SAI = 100 × number of stones/age), urine composition, stone composition, and sex. In 223 of the patients was it possible to calculate AP(CaOx) indexs, a standardized estimate of the ion-activity product of calcium oxalate. Results: The 446 patients (329 men, 117 women) who were considered representative of an average population of recurrent calcium stone formers, had a 5-year recurrence risk of approximately 50%. Patients with an SAI <2 had a lower recurrence risk than those with an SAI >2 and a corresponding difference was recorded between patients with SAI levels <5 and >5. Furthermore, female patients had a lower risk of new stone formation than male patients. Patients with an AP(CaOx) indexs of 1.5 or more had a significantly higher recurrence risk than those with a lower index, a difference that was most pronounced in female stone formers. A slightly higher risk of recurrent stone formation during the follow-up period could also be related to the presence of calcium phosphate in the stone, a high AP(CaP) indexs (a standardized estimate of the ion-activity product of calcium phosphate) and a low concentration of citrate. Conclusion: AP(CaOx) indexs and SAI were the most obvious predictors of the recurrence risk and these two variables, together with information on the sex distribution, might be useful for deriving an expected recurrence risk at a defined point of time in a group of recurrent stone formers. Such an estimate can be valuable for conclusions on the efficacy of different stone-preventive treatments when an appropriate control group is lacking.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Churchill DN: Medical treatment to prevent recurrent calcium urolithiasis. A guide to critical appraisal. Mineral Electrolyte Metab 1987;13:294–304.
  2. Bek-Jensen H, Tiselius HG: Stone formation and urine composition in calcium stone formers without medical treatment. Eur Urol 1989;16:144–150.
  3. Hofbauer J, Höbarth K, Ludvik G, Marbereger M: The ‘stone clinic effect’: Myth or reality? Eur Urol 1994;26:309–313.
  4. Williams RE: Long-term survey of 538 patients with upper urinary tract stone. Br J Urol 1963;35:416–427.
  5. Almby B, Meirik O, Schönebeck J: Incidence, morbidity and complications of renal and ureteral calculi in a well-defined geographical area. Scand J Urol Nephrol 1975;9:249–253.

    External Resources

  6. Coe FL, Keck J, Norton E: The natural history of untreated calcium nephrolithiasis. JAMA 1977;238:1519–1523.
  7. Ettinger B: Recurrence of nephrolithiasis. A six-year prospective study. Am J Med 1979;67:245–248.

    External Resources

  8. Wilson DM: Clinical and laboratory evaluation of stone patients. Endocrinol Metab Clin North Am 1990;19:773–801.
  9. Di Silverio F, D’Angelo AR, Gallucci M, Seccareccia F, Menotti A: Incidence and prediction of stone recurrence after lithotripsy in idiopathic calcium stone patients: A multivariate approach. Eur Urol 1996;29:41–46.

    External Resources

  10. Tiselius HG: Recurrent stone formation in patients treated with extracorporeal shock wave lithotripsy. J Stone Dis 1992;4:152–157.
  11. Ahlstrand C, Tiselius HG: Recurrences during a 10-year follow-up period after first renal stone episode. Urol Res 1990;18:397–399.
  12. Tiselius HG: Standard estimate of the ion activity product of calcium oxalate in urine from stone formers. Eur Urol 1989;16:48–50.
  13. Tiselius HG: Aspects on estimation of the risk of calcium oxalate crystallization in urine. Urol Int 1991;47:255–259.
  14. Tiselius HG: A simplified estimate of ion-activity product of calcium phosphate in urine. Eur Urol 1984;10:191–195.
  15. Larsson L, Sörbo B, Tiselius HG, Öhman S: A new method for quantitative wet chemical analysis of urinary calculi in the principles for calculation of results and mass recovery by an algorithm; in Urolithiasis and Related Clinical Research, New York, Plenum Press, 1985, pp 695–698.
  16. Coe FL: Calcium stones; in Nephrolithiasis, Pathogenesis and Treatment. Chicago, Year Book Medical, 1978, pp 6–16.
  17. Parks JH, Coe FL: An increasing number of calcium oxalate stone events worsens treatment outcome. Kidney Int 1994;45:1722–1730.
  18. Tiselius HG, Sandvall K: How are urine composition and stone disease affected by therapeutic measures at an outpatient clinic? Eur Urol 1990;17:206–212.
  19. Tiselius HG: Risk formulas in calcium oxalate urolithiasis. World J Urol 1997;15:176–185.
  20. Strauss AL, Coe FL, Deutsch L, Parks JH: Factors that predict relapse of calcium nephrolithiasis during treatment. A prospective study. Am J Med 1982;72:17–24.

    External Resources

  21. Tiselius HG: Relationship between the severity of renal stone disease and urine composition. Eur Urol 1979;5:323–327.

    External Resources

  22. Blandy JP, Marshall VR: Size of renal calculi, recurrence rate and follow-up. Br J Urol 1976;48:525–530.

    External Resources

  23. Tiselius HG, Bek-Jensen H, Fornander AM, Nilsson MA: Crystallization properties in urine from calcium oxalate stone formers. J Urol 1995;154:940–946.
  24. Bek-Jensen H, Tiselius HG: Repeated urine analysis in patients with calcium stone disease. Eur Urol 1998;33:323–332.
  25. Asplin J, Parks J, Lingeman J, Kahnoski R, Mardis H, Lacey S, Goldfarb D, Grasso M, Coe F: Supersaturation and stone composition in a network of dispersed treatment sites. J Urol 1998;159:1821–1825.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50